Literature DB >> 16385491

New prospects for autoimmune disease therapy: B cells on deathwatch.

E William St Clair, Thomas F Tedder.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16385491     DOI： 10.1002/art.21525

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  9 in total

Review 1.  Immunomodulatory approaches to the management of chronic urticaria: an immune-mediated inflammatory disease.

Authors:  Clifton O Bingham
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.806

2.  Protective and pathogenic roles for B cells during systemic autoimmunity in NZB/W F1 mice.

Authors:  Karen M Haas; Rei Watanabe; Takashi Matsushita; Hiroko Nakashima; Nobuko Ishiura; Hitoshi Okochi; Manabu Fujimoto; Thomas F Tedder
Journal:  J Immunol       Date:  2010-04-05       Impact factor: 5.422

3.  Fcgamma receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity.

Authors:  Thomas F Tedder; Aris Baras; Yan Xiu
Journal:  Springer Semin Immunopathol       Date:  2006-11-08

Review 4.  Translational Mini-Review Series on B Cell-Directed Therapies: Recent advances in B cell-directed biological therapies for autoimmune disorders.

Authors:  M C Levesque
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

5.  Early recovery of CD4 T cell receptor diversity after "lymphoablative" conditioning and autologous CD34 cell transplantation.

Authors:  Jan Storek; Zhao Zhao; Yiping Liu; Richard Nash; Peter McSweeney; David G Maloney
Journal:  Biol Blood Marrow Transplant       Date:  2008-12       Impact factor: 5.742

6.  Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis.

Authors:  M Odaka; M Hasegawa; Y Hamaguchi; N Ishiura; S Kumada; T Matsushita; K Komura; S Sato; K Takehara; M Fujimoto
Journal:  Clin Exp Immunol       Date:  2009-11-16       Impact factor: 4.330

7.  Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study.

Authors:  Serge D Steinfeld; Laure Tant; Gerd R Burmester; Nick K W Teoh; William A Wegener; David M Goldenberg; Olivier Pradier
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

8.  Model-Informed Dosing of Venetoclax in Healthy Subjects: An Exposure-Response Analysis.

Authors:  Nimita Dave; Sathej Gopalakrishnan; Sven Mensing; Ahmed Hamed Salem
Journal:  Clin Transl Sci       Date:  2019-08-07       Impact factor: 4.689

Review 9.  Treatment of systemic sclerosis: potential role for stem cell transplantation.

Authors:  Wen Xiong; Chris T Derk
Journal:  Stem Cells Cloning       Date:  2009-11-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.